Table 1.

Phase III studies in ES-SCLC. OS: overall survival, HR: hazard ratio, CT: chemotherapy, ICIs: immune checkpoint inhibitors.

References	Clinical Trial	Drugs	OS (Months)		HR
			CT + ICIs	CT
Horn L, 2018 [5]	IMpower133	Atezolizumab, carboplatin plus etoposide	12.3	10.3	0.70
Goldman JW, 2021 [6]	CASPIAN	PE plus durvalumab or PE plus durvalumab and the CTLA-4 inhibitor Tremelimumab	12.9	10.5	0.75
Wang, J, 2022 [8]	CAPSTONE-1	Adebrelimab, carboplatin plus etoposide	15.3	12.8	0.72
Cheng, Y, 2022 [9]	ASTRUM005	Serplulimab, carboplatin plus etoposide	15.4	10.9	0.63
Cheng, Y, 2023 [10]	RATIONALE-312	PE plus tislelizumab	15.5	13.5	0.75
Cheng, Y, 2023 [11]	ETER701	Benmelstobart with anlotinib, carboplatin plus etoposide	19.3	11.9	0.61